Science 2026-03-12 3 min read

Treating ADHD in teens with substance use disorder cuts mortality by 30% - but doctors hesitate to prescribe

A study of 1.2 million young people finds that clinicians pull back on stimulant prescriptions after a substance use diagnosis, despite evidence that treatment dramatically improves outcomes.

ADHD medication - including stimulants - is associated with a 30% reduction in five-year mortality risk for young people who have both ADHD and substance use disorder. Yet clinicians are pulling back on prescriptions for exactly the patients who appear to benefit most.

That is the core tension in a new study published in the Journal of the American Academy of Child and Adolescent Psychiatry, led by researchers at Penn State College of Medicine. The findings expose a treatment gap driven by understandable but potentially harmful clinical caution.

The fear behind the prescribing drop

Central nervous system stimulants - medications like methylphenidate and amphetamine salts - are the first-line pharmacological treatment for ADHD. They have higher response rates than non-stimulant alternatives. But they are also controlled substances with FDA warnings about misuse potential. When a young person already struggles with substance use disorder, the instinct to avoid adding another controlled substance to the picture is powerful.

The data suggest that instinct comes at a cost. Among the study population, ongoing stimulant prescriptions dropped by approximately 15% after a substance use disorder diagnosis, and new stimulant prescriptions fell by more than 17%. Clinicians appear to be steering patients away from the most effective ADHD treatment precisely when co-occurring conditions make effective treatment most urgent.

What the numbers show

The research team examined de-identified health records from over 1.2 million adolescents and young adults aged 15 to 25 diagnosed with ADHD. Of these, roughly 288,000 also carried a substance use disorder diagnosis, ranging from nicotine to alcohol, cocaine, and opioid use disorders.

Among the dual-diagnosis group, those receiving ADHD medication - whether stimulants or non-stimulants - showed measurably better outcomes across nearly every metric the researchers tracked:

Fewer hospitalizations and emergency room visits
Fewer accidental overdoses
Fewer suicidal thoughts and suicide attempts
More consistent engagement with psychiatric services
A 30% lower risk of death over five years

Stimulants specifically outperformed non-stimulant alternatives on several measures. Suicidal ideation and suicide attempts were 4% lower among those treated with stimulants compared to non-stimulant medications.

The 50% overlap

The connection between ADHD and substance use disorder is not coincidental. Up to half of individuals diagnosed with ADHD eventually develop a substance use disorder, and the combination produces outcomes worse than either condition alone. These patients face higher rates of hospitalization, suicidal ideation, and suicide attempts.

ADHD itself involves impaired executive function - the cognitive machinery that governs impulse control, planning, and behavioral regulation. Left untreated, these deficits can drive the very risk-taking and self-medication behaviors that feed substance use disorders. Treating the ADHD may, in effect, address one of the upstream drivers of the substance problem.

Correlation, not causation - but a strong signal

This was a retrospective cohort study, not a randomized trial. The researchers cannot say definitively that ADHD medication caused the improved outcomes. People who receive and maintain ADHD treatment may differ systematically from those who do not - in severity, insurance access, family support, or other unmeasured factors.

The study also relied on health records, which capture prescriptions written but not necessarily medications taken. Adherence is a persistent challenge in both ADHD and substance use disorder treatment.

But the magnitude and consistency of the associations across multiple outcome measures, combined with biological plausibility, make a compelling case that withholding ADHD treatment from young people with co-occurring substance use disorder may do more harm than the prescribing risk it aims to avoid.

What comes next

The research team is expanding its analysis to a broader age range of 16 to 65, examining how demographic factors like sex, race, and ethnicity, along with the specific type of substance use disorder, influence treatment patterns and outcomes. The goal is to provide clinicians with more granular guidance for navigating a decision that, as the current data make clear, carries consequences in both directions.

Source: Published in the Journal of the American Academy of Child and Adolescent Psychiatry. First author: Raman Baweja, Penn State College of Medicine. Senior author: James Waxmonsky, Penn State College of Medicine. Additional authors from Mayo Clinic, University of California San Diego, University of Pittsburgh, and Massachusetts General Hospital/Harvard Medical School. Funded by the National Center for Advancing Translational Sciences, NIH.